Peptides Defined
Shop

Weight-loss evidence

AOD-9604 for Weight Loss: Evidence, FDA Status, and Safety Limits

A research-backed review of AOD-9604 weight-loss claims, human trial limits, preclinical lipolysis data, FDA compounding concerns, WADA status, and research-market safety gaps.

By
PD Team
Published
May 31, 2026
Last updated
May 31, 2026
Read time
12 min read
Citations
9 citations
Review
Editorially reviewed by PD Team
A dark scientific desk with an unlabeled peptide vial, metabolic chart panels, molecular overlays, and clinical research visuals.

AOD-9604 is one of the clearer examples of a peptide topic where the marketing version and the evidence version can diverge. Search results and forum discussions often describe it as a targeted fat-loss peptide, a growth hormone fragment, or a gentler alternative to regulated weight-management drugs. The scientific record is more limited and more mixed.

The useful question is not whether AOD-9604 has any biological rationale. It does. The useful question is whether that rationale produced convincing human weight-loss evidence, and whether a product sold online as AOD-9604 should be treated as equivalent to a controlled clinical research material. Those are different questions.

This review separates human evidence, preclinical lipid-metabolism research, compounding status, anti-doping context, and research-market safety gaps. For broader context on regulated peptide medicines versus research-market products, start with approved, investigational, compounded, and research peptides.

Evidence Snapshot

Common claim Evidence picture Boundary
AOD-9604 burns fat like growth hormone. AOD-9604 was designed from a C-terminal fragment of human growth hormone and has preclinical lipolysis and lipid-metabolism data. Fragment biology does not mean it reproduces growth-hormone effects or produces meaningful human weight loss.
Human studies settle the weight-loss question. Human trials were conducted, and a published safety review summarizes several AOD-9604 studies in adults. The publicly available clinical evidence does not support confident consumer claims about large or reliable weight loss.
Animal fat-loss findings translate directly. Obese rat and mouse studies reported changes in weight gain, lipid metabolism, beta-3 adrenergic receptor expression, or fat oxidation. Animal metabolic models are not a substitute for controlled human outcome trials.
AOD-9604 is a legal compounding shortcut. FDA materials identify AOD-9604-related compounding concerns, including immunogenicity, peptide impurities, and limited safety information. A product name or research-use label does not establish an FDA-approved product, a lawful compounded product, or injectable quality.
It is irrelevant to athletes because it is not full GH. A PubMed-indexed anti-doping paper describes AOD-9604 as banned by WADA and developed detection methods. Tested athletes should treat WADA status as a separate risk from medical evidence or vendor wording.

What AOD-9604 Is

AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone. The commonly cited sequence is related to amino acids 177 to 191 of human growth hormone, with an added tyrosine residue at the N-terminus. It was developed around the idea that a smaller fragment might capture selected lipid-metabolism effects without the broader growth-promoting and glucose-related effects associated with full-length growth hormone.

That mechanism story is why AOD-9604 gets grouped with weight-loss peptides, growth hormone fragments, and body-composition products. It is not a GLP-1 receptor agonist like semaglutide, and it is not an approved GHRH analog medicine like tesamorelin in its labeled indication. It also should not be flattened into the same category as CJC-1295, which is discussed through GH and IGF-1 biomarker changes rather than a C-terminal growth hormone fragment.

This distinction matters for search intent. Someone comparing AOD-9604 with GLP-1 drugs is really comparing a mostly research-market peptide with heavily studied and regulated metabolic medicines. The GLP-1 drugs vs other peptides guide explains why evidence quality differs across those categories.

The name also does not answer practical product questions. A clinical-study material, a substance discussed in FDA compounding materials, and a research-use vial sold online can share a name while differing in identity testing, impurities, sterility, formulation, stability, route, and oversight. Those differences matter most when the route is injectable.

What The Human Evidence Shows

AOD-9604 has more human history than many research peptides, but that does not make the evidence simple. A published safety review states that six human clinical trials were performed between 2001 and 2006 and that 893 adults participated across those studies. That review is useful for understanding the development program, but it is not the same as a modern, PubMed-indexed obesity outcomes package with full trial reports, current regulatory review, and an approved label.

FDA's Pharmacy Compounding Advisory Committee materials are also relevant because they reviewed AOD-9604 and AOD-9604 acetate in the compounding context. Those materials cite the preclinical metabolic literature and summarize clinical-development information, but they do not convert AOD-9604 into an FDA-approved obesity drug.

The public clinical picture is cautious: early development suggested tolerability and metabolic selectivity, but the human weight-loss evidence did not establish AOD-9604 as a regulated weight-management medicine. Claims that it reliably targets stubborn fat, replaces GLP-1 therapy, or produces large weight changes are not supported by the evidence base used here.

A comparison with GLP-1 and incretin therapies helps show the gap. Articles on retatrutide, tirzepatide, and semaglutide and cagrilintide and CagriSema can cite large controlled trial programs with clear endpoints and ongoing regulatory milestones. AOD-9604 does not have that same published clinical footprint for obesity treatment.

Human safety language also needs restraint. A small or selective development dataset can miss uncommon events, long-term issues, risks in excluded populations, product-quality problems, or route-specific problems. Safety findings from a controlled study do not certify research-market material, compounded material, or a different route.

The practical summary is narrow: AOD-9604 has human clinical-development history and a published human safety review, but that history does not justify confident consumer weight-loss claims. It is better described as a peptide with preclinical lipid-metabolism rationale, limited public human outcome evidence, and important regulatory and product-quality concerns.

Preclinical Lipolysis And Cartilage Data

The strongest PubMed-indexed AOD-9604 evidence is mechanistic and preclinical. One early rat study reported that oral AOD-9604 reduced weight gain in obese Zucker rats and increased lipolytic activity in adipose tissue. The same abstract contrasted AOD-9604 with full human growth hormone in insulin-sensitivity findings within that animal model.

A related mouse study tested human growth hormone and AOD-9604 in obese mice and beta-3 adrenergic receptor knock-out mice. It reported changes in body weight, body fat, lipid metabolism, beta-3 adrenergic receptor expression, energy expenditure, and fat oxidation under defined experimental conditions. These findings support a lipid-metabolism research rationale, but they are still animal data.

Preclinical findings can be useful without being clinically decisive. A pathway may work in rodents and still produce small, inconsistent, or clinically unhelpful effects in humans. That is a common translation problem in metabolic research. The same principle applies to MOTS-c, where the MOTS-c evidence review separates animal and human biomarker work from weight-loss claims.

AOD-9604 has also been studied outside obesity. A rabbit osteoarthritis model evaluated intra-articular AOD-9604 with or without hyaluronic acid and reported cartilage-related findings. That is an orthopedic preclinical model. It should not be repackaged as evidence that AOD-9604 improves human joint symptoms, injury recovery, or body composition.

The anti-doping literature adds another angle. A PubMed-indexed Drug Testing and Analysis paper describes AOD-9604 detection and in vitro metabolism, noting its availability on internet sites and its WADA-banned status. That source is not a weight-loss trial. It is useful because it documents real-world circulation and sports-testing relevance.

Readers trying to judge study strength should look at species, route, endpoint, comparator, duration, sample size, and whether the outcome is a biomarker or a patient-centered result. The how to read a peptide study guide is the better starting point for that kind of evidence sorting.

FDA Status, Compounding, And Safety Limits

AOD-9604 should not be described as an FDA-approved weight-loss medication. FDA materials discussing AOD-9604 are compounding and advisory materials, not a prescribing label. The FDA compounding framework also matters because compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before marketing.

FDA's safety-risk page lists AOD-9604 among bulk drug substances that may present significant safety risks in compounding. The agency cites potential immunogenicity for certain routes, peptide-related impurity and active-ingredient characterization complexity, no or limited safety-related information, and serious adverse events that may be associated with AOD-9604, while noting that causality is not clear.

That wording should be read carefully. It does not say every exposure causes harm. It says FDA lacks enough information to know whether harm would occur when administered to humans, and it identifies quality and route-related risks that matter for peptide products. That is very different from vendor language that treats a vial name as sufficient assurance.

FDA's PCAC materials also make clear that the compounding question is not just demand. It involves clinical need, available evidence, product characterization, safety information, and quality controls. A substance can be popular online and still fail to meet the conditions for a lawful, reliable compounding pathway.

The reconstitution and concentration issue is separate. A calculator can help with arithmetic, so the reconstitution calculator is useful for understanding units. It cannot confirm identity, sterility, endotoxin status, peptide purity, route suitability, legality, dose, or medical appropriateness.

Athletes have an additional issue. WADA's prohibited list and anti-doping literature should be treated as independent constraints. If a substance is prohibited for sport, a "research use only" label or a claim that it is not full human growth hormone does not remove anti-doping responsibility.

How To Evaluate AOD-9604 Claims

First, ask whether the claim is about fat metabolism, weight change, body composition, cartilage biology, anti-doping status, or product legality. These are different questions. A rodent lipid-metabolism result does not answer human obesity outcomes. A safety review does not answer whether a research-market product is sterile. A WADA detection paper does not show body-composition benefit.

Second, ask which source supports the claim. PubMed-indexed preclinical papers support mechanism discussion. FDA materials support regulatory and safety-context statements. Human clinical-development summaries support cautious statements about what was studied. None of those sources support dosing protocols, stacking instructions, or guaranteed fat-loss claims.

Third, compare the claim with better-studied alternatives only on the right terms. Semaglutide has FDA-approved indications and large trial programs; AOD-9604 does not. Tesamorelin has a specific approved metabolic indication; AOD-9604 does not. That does not make every approved medicine right for every person. It means the evidence and oversight are different.

Finally, watch for vague language around "GH fragment," "targeted fat loss," "non-hormonal," "no side effects," and "GLP-1 stack." Those phrases can sound scientific while skipping the central questions: human outcome data, product quality, legal status, route, adverse-event monitoring, and medical context.

A conservative reading is the most honest one. AOD-9604 is a biologically interesting growth hormone fragment with preclinical lipid-metabolism findings and limited public human weight-loss evidence. It is not an FDA-approved weight-loss drug, and online or compounded-product claims should be read against FDA safety and quality concerns.

References

Disclaimer

This page is educational and is not medical advice. It does not provide dosing, injection, compounding, reconstitution, stacking, sourcing, storage, weight-loss treatment, sports-compliance advice, or individualized medical guidance for AOD-9604 or related products. Medication and anti-doping decisions should be made with qualified professionals using current regulator-reviewed and sport-governing-body materials.